Splenectomy for an adult patient with refractory secondary hemophagocytic lymphohistiocytosis.

Abstract

Treatment regimens of secondary hemophagocytic lymphohistiocytosis (sHLH) are complicated and individualized. CHOP regimen is well known for the treatment of adult sHLH, but it was not so effective for the 56-year-old male patient in our study. Splenomegaly, one of clinical manifestations of HLH, has urged us to investigate the role of splenectomy in HLH patients. Splenectomy is not only beneficial to confirm the underlying diseases, but also beneficial for the treatment of HLH. Here, we present a case diagnosed as sHLH who has recovered from HLH following comprehensive treatment based on splenectomy. The therapeutic value of splenectomy in sHLH needs further study.

• Authors: Li-Juan Zhang, Su-Jiang Zhang, Ji Xu, Jian-Yong Li, Ling-Ling Wang, Yi-Xin Hu, Hong-Xia Qiu, Yong-Qian Shu
• Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie (Biomed Pharmacother) Vol. 65 Issue 6 Pg. 432-5 (Sep 2011) ISSN: 1950-6007 [Electronic] France
• PMID: 21873022 (Publication Type: Case Reports, Journal Article)
• Copyright: Copyright © 2011 Elsevier Masson SAS. All rights reserved.

Chemical References

• Vincristine
• Doxorubicin
• Cyclophosphamide
• Prednisone

Topics

• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Cyclophosphamide (therapeutic use)
• Doxorubicin (therapeutic use)
• Drug Resistance
• Humans
• Lymphohistiocytosis, Hemophagocytic (drug therapy, pathology, physiopathology, surgery)
• Male
• Middle Aged
• Prednisone (therapeutic use)
• Splenectomy
• Splenomegaly (etiology)
• Treatment Outcome
• Vincristine (therapeutic use)